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Abstract
Background: With the availability of effective anti-EGFR therapies for various solid malignancies, such as non-cell small 
lung cancer, colorectal cancer and squamous cell carcinoma of the head and neck, the knowledge of EGFR and K-RAS 
status becomes clinically important. The aim of this study was to analyse EGFR expression, EGFR gene copy number 
and EGFR and K-RAS mutations in two cohorts of squamous cell carcinomas, specifically anal canal and tonsil 
carcinomas.
Methods: Formalin fixed, paraffin-embedded tissues from anal and tonsil carcinoma were used. EGFR protein 
expression and EGFR gene copy number were analysed by means of immunohistochemistry and fluorescence in situ 
hybridisation. The somatic status of the EGFR gene was investigated by PCR using primers specific for exons 18 through 
21. For the K-RAS gene, PCR was performed using exon 2 specific primers.
Results: EGFR immunoreactivity was present in 36/43 (83.7%) of anal canal and in 20/24 (83.3%) of tonsil squamous cell 
carcinomas. EGFR amplification was absent in anal canal tumours (0/23), but could be identified in 4 of 24 tonsil 
tumours.
From 38 anal canal specimens, 26 specimens were successfully analysed for exon 18, 30 for exon 19, 34 for exon 20 and
30 for exon 21. No EGFR mutations were found in the investigated samples. Thirty samples were sequenced for K-RAS
exon 2 and no mutation was identified. From 24 tonsil specimens, 22 were successfully analysed for exon 18 and all 24
specimens for exon 19, 20 and 21. No EGFR mutations were found. Twenty-two samples were sequenced for K-RAS
exon 2 and one mutation c.53C > A was identified.
Conclusion: EGFR mutations were absent from squamous cell carcinoma of the anus and tonsils, but EGFR protein 
expression was detected in the majority of the cases. EGFR amplification was seen in tonsil but not in anal canal 
carcinomas. In our investigated panel, only one mutation in the K-RAS gene of a tonsil squamous cell carcinoma was 
identified. This indicates that EGFR and K-RAS mutation analysis is not useful as a screening test for sensitivity to anti-
EGFR therapy in anal canal and tonsil squamous cell carcinoma.
Background
With the recent progress in molecular biology, the tum-
origenesis of cancer is becoming better understood, and
clinical management has improved. Epidermal growth
factor receptor (EGFR) has been validated as a therapeu-
tic target in several human tumours, including colorectal
cancer (CRC), non-small cell lung cancer (NSCLC) and
squamous cell carcinoma of the head and neck (HNSCC).
Ligand occupancy of EGFR activates the RAS/RAF/
MAPK, STAT and PI3K/Akt signalling pathways, which
together modulate cellular proliferation, adhesion, angio-
genesis and migration [1,2].
Monoclonal antibodies directed against the extracellu-
lar domain of EGFR and small molecule inhibitors of the
tyrosine kinase domain of the receptor have been evalu-
ated in the treatment of several solid tumours including
CRC, NSCLC and HNSCC [3]. Cetuximab, a chimeric
humanized antibody, and panitumumab, a fully human-
ized monoclonal antibody have shown efficacy in combi-
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Page 2 of 9nation with chemotherapy and also as monotherapeutic
agents in CRC [4-6]. In NSCLC, approximately 85% of
patients who responded favourably to gefitinib or erlo-
tinib, two FDA-approved small-molecule EGFR-tyrosine-
kinase inhibitors, were shown to have somatic mutations
in the EGFR gene. Somatic EGFR mutations are primarily
located in exons 18 through 21 around the ATP-binding
pocket of the tyrosine kinase domain [7-10]. The most
common mutations are short deletions in exon 19 affect-
ing the amino acid sequence LREA (DelE746-A750) or a
point mutation in exon 21 resulting in the amino acid
change L858R. Increased EGFR gene copy number as
determined by fluorescence in situ hybridisation (FISH)
is known as a prognostic marker of progression-free sur-
vival and overall survival in HNSCC [11,12].
Several reports indicate that the presence of K-RAS
mutations are a predictor of resistance to cetuximab and
panitumumab therapy in metastatic colorectal cancer
patients [13-16].
Cetuximab has been approved by the EMEA and FDA
for HNSCC treatment. Recently, Vermorken et al. [17]
described that cetuximab was effective in combination
with platinum-based regimens for recurrent or meta-
static squamous cell carcinoma of the head and neck.
Knowledge of the expression, amplification and muta-
tion status of EGFR as well as downstream effectors such
as K-RAS would help us to better understand the
response of cancer patients to molecular targeted ther-
apy.
Anal canal carcinoma is a relatively rare gastrointestinal
malignancy with an increasing rate of incidence. The esti-
mated number of new cases in the United States in 2009
will reach about 5290 patients (2100 males and 3190
females). It is estimated that (of the afore-mentioned
number) 260 males and 450 females will die from anal
canal carcinoma [18]. It is now apparent that the develop-
ment of anal cancer is associated with infection by human
papillomavirus (HPV), usually sexually transmitted
[19,20]. In the literature, few data regarding EGFR and K-
RAS status in squamous cell carcinoma of the anal canal
is available [21-25].
HNSCC is the sixth most frequent cancer worldwide
[26]. Despite current therapeutic modalities, many
patients relapse or develop metastases, highlighting the
need for new therapeutic targets. Several reports have
described EGFR mutations in HNSCC patients, but these
are heterogeneous, show ethnic differences in the fre-
quency of occurrence, varying from 7% in Asians and to
0% to 4% in white patients [11,12,27-32]. In the literature,
data regarding K-RAS status in HNSCC from the western
world is scarce [33].
The aim of the present study was to analyse EGFR
expression, EGFR gene copy number and EGFR and K-
RAS mutational status in formalin-fixed, paraffin-embed-
ded specimens from two cohorts of patients with
squamous cell carcinoma, anal canal and tonsils.
Methods
Patient and sample characteristics
Formalin fixed, paraffin-embedded tissues from 51
squamous cell carcinomas of the anus and 24 squamous
cell carcinoma of the tonsil were retrieved from the
pathology departments of the participating institutions.
The tissues were biopsied or resected between 1995 and
2006. Five micron thick sections were stained with hae-
matoxylin and eosin for examination by light microscopy.
The patient and sample characteristics are presented in
Table 1. This study was approved by our local ethics com-
mittee. The number of evaluable cases for EGFR immu-
nostaining, EGFR FISH, EGFR and K-RAS mutation
analysis for the squamous cell carcinoma of the anus and
tonsil are also presented in Table 1.
EGFR immunohistochemistry
EGFR immunostaining was performed using the Ventana
system (Ventana Medical Systems Inc, Tucson, AZ). After
deparaffinisation, five micron-thick sections were
sequentially treated with inhibitor for 4 minutes and pro-
tease 1 for 6 minutes. Sections were then incubated with
anti-EGFR mouse monoclonal IgG1 antibody (Clone
31G7, Zymed Laboratories, South San Francisco, CA,
USA) for 32 minutes (1:100 dilution), after which they
were incubated sequentially with amplifier A, amplifier B,
biotinylated immunoglobulin, avidin-horseradish peroxi-
dase and diaminobenzidine (DAB) for 8 minutes each.
Sections were counterstained using haematoxylin for 6
minutes and bluing reagent for 2 minutes. All incubation
steps were performed at 37°C.
Specimens were evaluated microscopically. Stains were
considered positive when membrane staining of any
intensity occurred in tumour cells. According to their
staining intensity, positive samples were defined as weak
(1+), moderate (2+) or strong (3+).
EGFR-Fluorescence In Situ Hybridisation
Dual colour FISH was performed with the Vysis LSI
EGFR Dual Color probe (Abbott Molecular Inc., Des
Plaines, IL, USA) which hybridises to the band region
7p12 in SpectrumOrange and the centromere of chromo-
some 7 (7p11.1-q11.1, D7Z1 locus) in SpectrumGreen.
FISH was carried out according to the protocol of the
supplier.
For each slide, at least 20 neoplastic non-overlapping
nuclei were scored for signals from both CEP7 and EGFR
probes under the fluorescence microscope.
With a slight modification according to Cappuzzo et al.
[34], patients were classified into five groups with ascend-
ing EGFR gene copy numbers. Briefly, disomy was
defined as ≤ 2 copies in 90% of cells, trisomy as 3 copies in
Van Damme et al. BMC Cancer 2010, 10:189
http://www.biomedcentral.com/1471-2407/10/189
Page 3 of 910-40% of the cells, low polysomy as ≥ 4 copies in 10-40%
of cells, high polysomy as ≥ 4 copies in ≥ 40% of cells, and
EGFR amplification was considered to be present if > 10%
of the nuclei contained multiple EGFR signals and the
EGFR/CEP7 ratio was ≥ 2.
EGFR and K-RAS mutation analysis
Genomic DNA was isolated from 3 × 50-μm formalin
fixed, paraffin-embedded tissues specimens. These sec-
tions were cut and incubated with 500 μl of 1X phos-
phate-buffered saline (PBS) for 10 min at 80°C. After
centrifugation (10 min - 14000 ×g), paraffin and PBS were
removed. DNA was isolated using the Centra Puregene
tissue kit according to the manufacturers instructions
(Qiagen GmBH, Hilden, Germany).
The somatic status of the EGFR gene was investigated
by PCR using primers specific for exons 18-21, encom-
passing the tyrosine kinase domain. For the K-RAS gene,
PCR was performed using exon 2 specific primers. Subse-
quently, PCR fragments were analysed by direct sequenc-
ing in both sense and antisense direction. For ease of
sequencing, M13 tails were attached to every primer pair.
Primer sequences were as follows: EGFR exon 18 forward
primer: CCTGAGGTGACCCTTGTCTCTGTGTTCTT,
reverse primer: GAGGCCTGTGCCAGGGACCTTA,
EGFR exon 19 forward primer: CGCACCATCTCA-
CAATTGCCAGTTA and reverse primer: AAAGGTG-
GGCCTGAGGTTCA, EGFR exon 20 forward primer:
cacactgacgtgcctctcc and reverse primer: tatctcccctccccg-
tatct, EGFR exon 21 forward primer: CCCTCACAG-
CAGGGTCTTCTCTGT and reverse primer: TCAGG
AAAATGCTGGCTGACCTA, K-RAS exon 2 forward
primer: cgtcctgcaccagtaatatgc and reverse primer:
GTATTAACCTTATGTGTGACA. The following PCR
program was applied: 5 min 95°C, 30 sec 95°C, 30 sec
62°C, 30 sec 68°C (with the last three steps repeated 42
times) and 7 min 68°C.
Statistical analysis
Data were analysed using SPSS 15.0 software. Correla-
tions between EGFR protein expression and gene amplifi-
cation were evaluated using Pearson's χ2 test. P-value <
0.05 was considered statistically significant.
Table 1: Patient and sample characteristics.
Anal Canal (n = 51) Tonsils (n = 24)
Age (years)
Median 60 58
Range 35-85 43-80
Gender (number)
Male 25 18
Female 26 6
Specimens (number)
Biopsies 15 2
Resection 36 22
Histological findings (number)
Well differentiated SCC 17 5
Moderately differentiated SCC 20 13
Poorly differentiated SCC 14 6
Evaluable cases (number) for
EGFR immunostaining 43 24
EGFR FISH 23 24
EGFR mutation analysis
exon18 26 22
exon19 30 24
exon20 34 24
exon21 30 24
K-RAS mutation analysis 30 22
EGFR: Epidermal Growth Factor Receptor; FISH: Fluorescence In Situ Hybridisation; SCC: squamous cell carcinoma
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EGFR expression in squamous cell carcinomas of the anal 
canal and tonsils
The immunohistochemical findings of EGFR expression
are summarized in Table 2. EGFR expression analysis
could be performed on 47 of 51 anal canal specimens, due
to lack of sufficient material from the remaining four
specimens. Immunoreactivity to EGFR was not interpre-
table in 4 of the 47 cases. From the remaining 43 cases, 36
showed immunoreactivity to EGFR (83.7%). Among
them, 29 (67.4%) cases exhibited moderate (2+) or strong
(3+) staining intensities (Figure 1). There was no correla-
tion between EGFR expression and patient age (P = 0.45)
or differentiation grade (P = 0.82).
EGFR expression analysis could be determined in all
tonsil specimens. Twenty out of 24 showed immunoreac-
tivity to EGFR (83.3%). Among them, 10 (50%) cases
exhibited moderate (2+) or strong (3+) staining intensi-
ties. There was no correlation between EGFR expression
and patient age (P = 0.56) or differentiation grade (P =
0.52).
EGFR gene copy number in squamous cell carcinoma of the 
anal canal and tonsils
FISH analysis was performed on the same samples that
were used for immunohistochemical analysis. However, 8
anal canal specimens could not be investigated due to
technical problems and in 20 samples insufficient signal
intensity was obtained for proper interpretation. Of the
remaining 23 specimens, none showed EGFR gene ampli-
fication. EGFR disomy, trisomy, low polysomy and high
polysomy were detected in 4, 11, 6 and 2 anal canal tis-
sues, respectively (Table 3). The FISH patterns did not
correlate with EGFR immunostaining (P > 0.05).
All tonsil specimens could be investigated by FISH.
Four specimens showed EGFR gene amplification (EGFR/
CEP7 ratio ≥ 2) (Figure 2). In the remaining 20 tumours,
disomy, trisomy and low polysomy were detected in 4, 13
and 3 tonsil tissues respectively (Table 3). Again, the FISH
patterns did not correlate with EGFR immunostaining (P
> 0.05).
EGFR and K-RAS mutation analysis
In 10 of 51 anal canal specimens not enough material was
available for DNA extraction. For three resection speci-
mens sequence analysis failed for all investigated exons.
Those same three specimens also failed FISH analysis
indicating that most probably the fixation method of the
available tissue did not allow for downstream DNA-based
applications.
For EGFR mutation analysis exons 18 through 21 were
examined. From the 38 anal canal specimens, 26 speci-
mens were successfully analysed for exon 18, 30 for exon
19, 34 for exon 20 and 30 for exon 21. No EGFR muta-
tions were found in the investigated samples. For K-RAS
gene mutation analysis exon 2 was examined. Out of the
38 anal canal specimens, 30 were sequenced, and no
mutation was identified.
All tonsil specimens were representative for DNA
extraction. From those specimens, 22 were successfully
analysed for exon 18 and all 24 specimens were success-
fully analysed for exon 19, 20 and 21. No EGFR mutations
were found in the investigated samples. Out of the 24
specimens, 22 were sequenced for K-RAS exon 2 muta-
tion and one mutation c.53C > A (p.A18D) was identified
(Figure 3). This K-RAS mutated tonsil specimen showed
no EGFR gene amplification and exhibited weak EGFR
immunostaining.
Discussion
With the availability of effective anti-EGFR therapies for
various solid malignancies, such as NSCLC, CRC and
Table 2: Summary of Epidermal Growth Factor Receptor expression in anal canal and tonsil squamous cell carcinoma.
Immuno-
reactivity
No. (%) of cases
Anal Canal SCC (n = 43) Tonsil SCC (n = 24)
- 1+ 2+ 3+ - 1+ 2+ 3+
<5% 7 (16.3) 0 0 0 4 (16.7) 0 0 0
5-25% 0 4 (9.3) 2 (4.7) 1 (2.3) 0 6 (25) 0 1 (4.2)
26-50% 0 0 3 (7) 2 (4.7) 0 2 (8.3) 1 (4.2) 0
51-75% 0 1 (2.3) 4 (9.3) 2 (4.7) 0 2 (8.3) 1 (4.2) 2 (8.3)
>75% 0 2 (4.7) 3 (7) 12 (27.9) 0 0 2 (8.3) 3 (12.5)
Total 7 (16.3) 7 (16.3) 12 (28) 17 (39.6) 4 (16.7) 10 (41.6) 4 (16.7) 6 (25)
-: negative immunostaining 1+: weak immunostaining; 2+: moderate immunostaining; 3+: strong immunostaining; SCC: squamous cell 
carcinoma
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Figure 1 EGFR immunostaining. Anal canal squamous cell carcinoma, A to D. A. Weak immunostaining magnification x 100; B. Weak immunostain-
ing magnification x 200; C. Strong immunostaining magnification x 100; D. Strong immunostaining magnification x  200. Tonsil squamous cell carci-
noma, E and F. E. Immunostaining magnification x 100; F. Immunostaining magnification x 400. Arrows indicate membrane staining. For A, C and E, 
bar indicates 200 μm; B and D, 100 μm; and F 50 μm
A B
C D
FE
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becomes clinically important.
Currently, few data regarding EGFR expression in
squamous cell carcinoma of the anus are available [21-
24]. Le et al. [21] found positive EGFR staining in all sam-
ples, Alvarez et al. [22] described EGFR immunoreactiv-
ity in 55% of studied tumours, Zampino et al. [23]
reported positivity in 7 of the 12 evaluable cases and in
the cohort of Walker et al. [24] 96% of the invasive anal
canal cancers displayed EGFR immunoreactivity.
In the present study we showed immunohistochemical
evidence of EGFR expression (i.e., at least 5% of tumour
cells were positive) in 83.7% interpretable cases of
squamous cell carcinoma of the anus. EGFR is overex-
pressed in most epithelial malignancies including
HNSCC, ranging from 31 to 100% [32]. We showed EGFR
expression in 20 out of 24 cases (83.3%) of squamous cell
carcinoma of the tonsils. The results of the different
immunohistochemical studies were however not consis-
tent. These differences could be explained by the use of
different antibodies, immunohistochemical techniques
and scoring systems. Variations in EGFR immunoreactiv-
ity are also dependent on the fixation procedure and the
storage time of unstained tissue sections [35].
In the search for which patients will benefit from anti-
EGFR therapy, multiple studies investigating EGFR gene
amplification have been performed. Increased EGFR gene
copy number has been linked to poor prognosis in
NSCLC [10] and HNSCC [11,12].
In our study, like Alvarez et al. [22] and Walker et al.
[24], no EGFR gene amplification could be identified in
anal canal squamous cell carcinoma samples. The preva-
lence of increased EGFR gene copy number in HNSCC
varies in different studies, ranging between 13-58%
[11,12,36]. In the present study, four tonsil squamous cell
carcinomas showed EGFR gene amplification, defined as
a ratio of EGFR gene copies to CEP7 gene copies of at
least two in more than 10% of tumour cells. We found
EGFR protein expression was independent of EGFR gene
amplification. Although EGFR gene amplification was
identified in only four cases of tonsil squamous cell carci-
noma, it was not possible to correlate this finding with
patient outcome.
Approximately 85% of NSCLC patients who responded
favourably to gefitinib or erlotinib were shown to have
somatic mutations in the EGFR gene [7-10]. About 90% of
EGFR mutations affect small regions of the gene usually
within exons 18 to 21, which encode for the EGFR
tyrosine kinase domain. Anti-EGFR treatment can pre-
vent activation of downstream signalling pathways such
as the PI3K/Akt, RAS/Erk and STAT pathways, resulting
in the inhibition of cellular proliferation and induction of
apoptosis.
No prior study has investigated EGFR gene mutation
status in squamous cell carcinoma of the anus. In our
panel, exons 18 to 21, encoding the EGFR tyrosine kinase
domain were investigated. No mutations in the EGFR
gene were identified which excludes overexpression being
the result of the presence of mutations.
Up to date there have been few studies searching for
mutations in HNSCC and the results are contradictory.
Table 3: EGFR status in anal canal and tonsil squamous cell carcinoma.
EGFR gene copy numbers Anal Canal SCC (n = 23)
No. (%)
Tonsil SCC (n = 24)
No. (%)
Disomy 4 (17.4) 4 (16.7)
Trisomy 11 (47.8) 13 (54.1)
Low polysomy 6 (26.1) 3 (12.5)
High polysomy 2 (8.7) 0
Amplification 0 4 (16.7)
SCC: squamous cell carcinoma
Figure 2 EGFR gene amplification by fluorescent in situ hybrid-
ization analysis in tonsil squamous cell carcinoma. FISH analysis 
was performed using SpectrumOrange EGFR probe (red signal) with a 
SpectumGreen CEP7 probe (green signal).
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of 41 Asian HNSCC patients (7.3%) and Na et al. [28]
described several changes in 17 out of 108 Korean
HNSCC patients (15.7%). Recently, one report analysed
91 Japanese HNSCC and 12 HNSCC cell lines for muta-
tions in EGFR, ErbB2 and K-RAS. Only one silent muta-
tion, C836T was found in exon 21 of EGFR in the UT-
SCC-16A cell line. No other mutations were found [29].
Chung et al. [11] reported that no EGFR-activating
mutations were found in 86 tumour samples from 82
American HNSCC patients. Temam et al. [12] also failed
to detect any EGFR mutation in 134 French and Ameri-
can HNSCC patients. Lemos-Gonzalez et al. [30] analy-
sed EGFR tyrosine kinase mutations from 31 Spanish
HNSCC patients and none displayed a somatic EGFR
mutation. Loeffler-Ragg et al. [31] screened 100 Cauca-
sian HNSCC patients and only one displayed a novel,
somatic EGFR missense mutation. From the same group
Schwentner et al. [32] reported a rare EGFR mutation p.
G796S in 2 out of 127 Austrian patients.
In our study, no EGFR mutations were found in tonsil
squamous cell carcinoma, which confirms that EGFR
kinase mutations are rare in Caucasian patients. It is
known from studies in other tumour types (e.g. NSCLC)
that somatic mutations in the tyrosine kinase domain of
EGFR are much more common in adenocarcinomas than
in squamous cell carcinoma [37]. Although the presence
of activating mutations was first related to the ethnicity, it
is now known that the frequency of EGFR mutations in
NSCLC patients is not different in Western or Asian pop-
ulations when the smoking habit is taken into account
[9,38]. Although it is not clear that the pattern of EGFR
mutations in NSCLC could be directly translated to
HNSCC, the low frequency of EGFR mutations, and the
fact that all but three patients included in our study are
significant current smokers, could explain the absence of
EGFR mutations in our subset of patients.
HPV-infection is a risk factor for head and neck, anal
canal, cervical and vulvar squamous cell carcinomas.
Recently, in head and neck and vulvar squamous cell car-
cinoma, EGFR mutations and protein overexpression
were predominantly HPV-negative and associated with
poorer prognoses [28,39]. Recently, Walker et al. [24]
investigated EGFR expression in anal HPV-infected
squamous intraepithelial lesions and/or invasive cancers.
In both HIV-positive and HIV-negative patients the
EGFR immunostaining increased from condyloma acum-
inata (HPV6 and 11 infected) through anal intraepithelial
neoplasia 1, 2 and 3 till invasive squamous carcinoma
(both infected with oncogenic HPV), highlighting the
effects of oncogenic HPVs. Also, HIV-positive status con-
tributes to augment EGFR expression levels involved in
carcinogenesis. However, in our study the HPV-status
and HIV-status was not systematically established. So, it
Figure 3 Sequence chromatogram displaying the K-RAS mutation c.53C > A (p.A18D) in exon 2 (arrow) in a patient with tonsil squamous 
cell carcinoma, analysed by direct sequencing.
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the HPV-status and HIV-status in anal squamous lesions.
Activating mutations in the K-RAS gene, which result in
EGFR-independent activation of the mitogen-activated
protein kinase pathway, are found in 35% of patients with
CRC and in 15 to 30% of patients with NSCLC. The
mutations are most frequently found in codon 12 and 13
of exon 2 of the K-RAS gene and are usually mutually
exclusive with EGFR mutations [3]. Recently, several
reports have indicated that K-RAS mutations are an
important predictor of resistance to cetuximab [13-15]
and panitumumab therapy [16] in metastatic colorectal
cancer patients and are associated with an unfavourable
prognosis.
Hiorns et al. [40] screened for activating mutations of
the ras oncogene family in anal carcinoma using DNA
amplified in vitro by PCR. Mutations were seen in two
cases, both in Ki-ras codon 12. In our anal canal panel,
exon 2 of K-RAS was investigated and no mutations were
found. Mutations of the RAS family constitute one of the
changes during cancer development. However, these
mutations differ based on cancer type and ethnicity of the
patients. In HNSCC patients from the western world
these mutations were relatively infrequent [33] while in
India they are very common [41]. In our tonsil carcinoma
panel, one K-RAS mutation, c.53C > A (p.A18D) was
identified. This specimen showed no EGFR gene amplifi-
cation and had weak EGFR immunostaining. To look for
the occurrence of this mutation, the COSMIC databank
http://www.sanger.ac.uk/genetics/CGP/cosmic was
screened and the c.53C > A mutation has been described
in one Japanese lung adenocarcinoma patient [42].
Conclusions
We can state that EGFR mutations were absent from
squamous cell carcinoma of the anus and tonsils, but that
EGFR protein expression was detected in the majority of
the cases. EGFR amplification was seen in tonsil but not
in anal canal carcinomas. In our investigated panel, only
one mutation in the K-RAS gene of a tonsil squamous cell
carcinoma was identified, indicating that EGFR and K-
RAS mutations are infrequent in this cohort of squamous
cell carcinomas. This indicates that EGFR and K-RAS
mutation analysis is not useful as a screening test for sen-
sitivity to anti-EGFR therapy in anal canal and tonsil
squamous cell carcinoma.
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